Rallybio Overview

  • Founded
  • 2018
Founded
  • Status
  • Public
  • Employees
  • 41
Employees
  • Stock Symbol
  • RLYB
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $9.74
  • (As of Monday Closing)

Rallybio General Information

Description

Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Contact Information

Website
www.rallybio.com
Formerly Known As
Rallybio Holdings
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • 234 Church Street
  • Suite 1020
  • New Haven, CT 06510
  • United States
+1 (203) 000-0000

Rallybio Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Rallybio Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.74 $9.89 $8.06 - $25.78 $318M 32.1M 72.7K -$2.24

Rallybio Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 634,143
Revenue 0 0 0
EBITDA (43,273) (25,000) (17,592)
Net Income (34,598)
Total Assets 193,865 141,858 21,607
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Rallybio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Rallybio‘s full profile, request access.

Request a free trial

Rallybio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transform
Drug Discovery
New Haven, CT
41 As of 2022
00000
0000 0000-00-00
00000000 00000

0000 000

ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
000000000000000
Newton, MA
00 As of 0000
0000
000000 - 000 0000

0000000

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
0000000000000
Irvine, CA
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rallybio Competitors (59)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Acer Therapeutics Formerly VC-backed Newton, MA 00 0000 000000 - 000 0000
0000000 Formerly VC-backed Irvine, CA 00 00000 000000 - 000 00000
000 00000000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000000 00000
0000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
00000000 000000000 Formerly VC-backed Newtown, PA 00 00000 00000000 00000
You’re viewing 5 of 59 competitors. Get the full list »

Rallybio Patents

  • 21

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Rallybio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2757596-T3 Antibodies against hpa-1a Active 31-Mar-2014 000000000
CA-2943857-A1 Antibodies against hpa-1a Pending 31-Mar-2014 000000000
US-10882919-B2 Antibodies against hpa-1a Active 31-Mar-2014 000000000
AU-2015239606-A1 Antibodies against hpa-1a Granted 31-Mar-2014 000000000
AU-2015239606-B2 Antibodies against hpa-1a Active 31-Mar-2014 C07K16/34
To view Rallybio’s complete patent history, request access »

Rallybio Executive Team (3)

Name Title Board Seat Contact Info
Martin Mackay Ph.D Chief Executive Officer & Chairman
Jeffrey Fryer Chief Financial Officer, Finance & Founder
Stephen Uden Chief Scientific Officer & Founder
To view Rallybio’s complete executive team members history, request access »

Rallybio Board Members (11)

Name Representing Role Since
Helen Boudreau Self Board Member 000 0000
Jamil Beg Self Board Observer 000 0000
Ketan Patel MD Self Board Member 000 0000
Kush Parmar Ph.D 5AM Ventures Board Member 000 0000
Lucian Iancovici MD Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Rallybio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rallybio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Rallybio‘s full profile, request access.

Request a free trial

Rallybio Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00 00000000 23-Jul-2019 00000 0000 Drug Discovery 0000000 0
Prophylix 28-Jun-2019 Merger/Acquisition Biotechnology
To view Rallybio’s complete investments and acquisitions history, request access »

Rallybio Subsidiaries (1)

Company Name Industry Location Founded
000000000 Biotechnology Tromsø, Norway 0000
To view Rallybio’s complete subsidiaries history, request access »